Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma.
- Author:
Yihebali CHI
1
;
Jian-Hong REN
;
Lin YANG
;
Cheng-Xu CUI
;
Jun-Ling LI
;
Jin-Wan WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; Antimetabolites, Antineoplastic; administration & dosage; Antineoplastic Agents; administration & dosage; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Cisplatin; administration & dosage; Female; Fluorouracil; administration & dosage; Humans; Male; Middle Aged; Stomach Neoplasms; drug therapy; Taxoids; administration & dosage
- From: Chinese Medical Journal 2011;124(19):2997-3002
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDA phase III trial involving docetaxel, cisplatin, and fluorouracil (DCF) in the treatment of advanced gastric cancer was shown to have superior efficacy compared to cisplatin and fluorouracil alone, but with a high rate of hematologic toxicity. To reduce toxicity while maintaining the efficacy of DCF, we reduced the doses of docetaxel (D) and cis-platinum (CDDP), and administered 5-fluorouracil (5-FU) via a continuous intravenous (CIV) infusion.
METHODSChemotherapy-naive patients with gastric adenocarcinomas received D (60 mg/m(2) 1 hour on day 1), CDDP (30 mg/m(2) on days 1 and 2), and 5-FU (1500 mg×m(-2)×24 h(-1) CIV on days 1 and 8 every 3 weeks). The primary endpoint was the response rate.
RESULTSFourteen patients were enrolled. Based on the efficacy evaluation following at least 2 cycles of treatment, there was 7.1% complete remission (CR), 71% partial remission (PR), 14% stable disease (NC/SD), and 7.1% progressive disease (PD). The median survival time was 13 months. Nine patients (64%) had grade III-IV neutropenia, and 4 patients (29%) had grade IV neutropenia, among whom 1 had grade IV neutropenia with grade III nausea and vomiting.
CONCLUSIONThe modified DCF regimen is highly active and has a favorable toxicity profile in Chinese patients with gastric cancer.
